<DOC>
	<DOC>NCT02232594</DOC>
	<brief_summary>The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual速 metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Berodual速 Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Fenoterol, ipratropium drug combination</mesh_term>
	<mesh_term>Fenoterol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Patients of either sex over 40 years with the symptoms of a chronic obstructive airways disease Only patients which have not been treated with Berodual速 within the last year should be included Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berodual速 metereddose inhaler</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>